Sysmex (OTCMKTS:SSMXY) Reaches New 12-Month Low - Time to Sell?

Key Points

• Sysmex shares hit a new 52-week low at $11.93, down from a previous close of $12.25, with a trading volume of 53,663 shares.
• Despite the stock's decline, Zacks Research upgraded its rating from "strong sell" to "hold", indicating a more stable outlook.
• In its latest earnings report, Sysmex reported a net revenue of $717.09 million, falling short of expectations of $807.27 million and an earnings per share of $0.05, underperforming against the consensus estimate of $0.12.

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $11.93 and last traded at $11.93, with a volume of 53663 shares trading hands. The stock had previously closed at $12.25.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of Sysmex from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Sysmex has an average rating of "Hold".

Sysmex Trading Down 2.2%

The company has a quick ratio of 2.49, a current ratio of 3.37 and a debt-to-equity ratio of 0.12. The company's 50-day moving average price is $13.68 and its 200-day moving average price is $16.30. The firm has a market cap of $7.54 billion, a price-to-earnings ratio of 23.95 and a beta of 1.16.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.07). Sysmex had a net margin of 9.35% and a return on equity of 10.20%. The company had revenue of $717.09 million during the quarter, compared to analysts' expectations of $807.27 million. Equities analysts expect that Sysmex Corporation ADR will post 0.57 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.